Iovance Biotherapeutics (LTS:0JDK) 3-Year Book Growth Rate : -20.10% (As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Iovance Biotherapeutics 3-Year Book Growth Rate?

Iovance Biotherapeutics's Book Value per Share for the quarter that ended in Dec. 2023 was $2.28.

During the past 12 months, Iovance Biotherapeutics's average Book Value per Share Growth Rate was -14.20% per year. During the past 3 years, the average Book Value per Share Growth Rate was -20.10% per year. During the past 5 years, the average Book Value per Share Growth Rate was -6.30% per year. During the past 10 years, the average Book Value per Share Growth Rate was 10.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

During the past 13 years, the highest 3-Year average Book Value per Share Growth Rate of Iovance Biotherapeutics was 45.00% per year. The lowest was -815.80% per year. And the median was 2.80% per year.

Competitive Comparison of Iovance Biotherapeutics's 3-Year Book Growth Rate

For the Biotechnology subindustry, Iovance Biotherapeutics's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Iovance Biotherapeutics's 3-Year Book Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Iovance Biotherapeutics's 3-Year Book Growth Rate distribution charts can be found below:

* The bar in red indicates where Iovance Biotherapeutics's 3-Year Book Growth Rate falls into.

Iovance Biotherapeutics 3-Year Book Growth Rate Calculation

This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

Iovance Biotherapeutics (LTS:0JDK) 3-Year Book Growth Rate Explanation

Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.

Iovance Biotherapeutics 3-Year Book Growth Rate Related Terms

Thank you for viewing the detailed overview of Iovance Biotherapeutics's 3-Year Book Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Iovance Biotherapeutics (LTS:0JDK) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Iovance Biotherapeutics Inc (LTS:0JDK) » Definitions » 3-Year Book Growth Rate

Comparable Companies

Traded in Other Exchanges

IOVA:USA 2LB:Germany

Address

825 Industrial Road, Suite 400, San Carlos, CA, USA, 94070

Website

https://www.iovance.com

Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approval and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.

Iovance Biotherapeutics (LTS:0JDK) Headlines

No Headlines